Welcome to our dedicated page for KESTRA MEDICAL TECHNOLOGIES, LTD. SEC filings (Ticker: KMTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on KESTRA MEDICAL TECHNOLOGIES, LTD.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into KESTRA MEDICAL TECHNOLOGIES, LTD.'s regulatory disclosures and financial reporting.
Kestra Medical Technologies, Ltd. has a planned sale of 6,995 shares of common stock through Merrill Lynch on NASDAQ on 08/04/2026. These shares relate to the 07/17/2026 vesting of performance share unit awards granted under the issuer’s equity compensation plan.
The filing also lists prior sales by Vaseem Mahboob over the past three months: 3,980 shares on 07/30/2026 for 90,560.62, 8,817 shares on 07/31/2026 for 199,344.62, and 5,391 shares on 08/03/2026 for 128,312.27.
Kestra Medical Technologies Chief Business Officer Timothy P. Moran reported nondiscretionary sales of 15,256 common shares to cover tax withholding arising from vested restricted stock units. The shares were sold on July 30, July 31 and August 3, 2026 at weighted average prices of $22.7735, $22.6054 and $23.7611 per share within intraday ranges from $22.15 to $23.98.
Kestra Medical Technologies’ Chief Commercial Officer Alfred J. Ford Jr. reported selling a total of 27,632 Common Shares of KMTS across three transactions on July 30, July 31, and August 3, 2026. These sales, reported as open‑market or private transactions at weighted‑average prices between $22.17 and $24.28 per share, are described as nondiscretionary “sell‑to‑cover” trades made to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units.
Kestra Medical Technologies Chief Financial Officer Mahboob Vaseem reported sales of 18,188 Common Shares in three transactions on July 30, July 31, and August 3, 2026. The footnotes state these were nondiscretionary sell to cover transactions executed solely to satisfy tax withholding obligations from the vesting and settlement of restricted stock units, with each day’s sales priced at a weighted average within disclosed ranges.
Kestra Medical Technologies, Ltd. insider Traci S. Umberger, a director and officer, reported selling a total of 22229 Common Shares in three open-market or private transactions on July 30, July 31, and August 3, 2026. Footnotes state these were nondiscretionary sell-to-cover sales required to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units, executed at weighted-average prices within ranges from about $22.17 to $24.28 per share.
Kestra Medical Technologies president and CEO Brian Daniel Webster reported sales of 29,822 common shares of KMTS in three transactions on July 30, July 31 and August 3, 2026. The shares were sold at weighted average prices between $22.0577 and $24.1100 solely to cover tax withholding obligations from the vesting and settlement of restricted stock units.
Kestra Medical Technologies, Ltd. (KMTS) reports a planned sale of 13,015 shares of common stock through Merrill Lynch on or about 07/31/2026, to be traded on NASDAQ. These shares relate to performance share unit awards that vested on 07/17/2026 and were granted under the issuer’s equity compensation plan.
Alfred J. Ford previously sold 5,936 shares of common stock for $135,120.73 on 07/30/2026 and 8,681 shares for $196,284.58 on 07/31/2026.
Kestra Medical Technologies, Ltd. reported a planned sale of 5,391 shares of common stock through Merrill Lynch on the NASDAQ on 08/03/2026, with an indicated value of $128,312.27. The shares relate to performance share unit awards that vested on 07/17/2026 under the issuer’s equity compensation plan. In the prior three months, Vaseem Mahboob sold 3,980 shares for $90,560.62 on 07/30/2026 and 8,817 shares for $199,344.62 on 07/31/2026.
Kestra Medical Technologies, Ltd. (KMTS) has a selling securityholder, Traci Umberger, filing to sell common stock under Rule 144. The planned transaction lists 7,590 shares of common stock to be sold through Merrill Lynch on or after 08/03/2026, with an indicated value of $181,061.84 on NASDAQ.
The shares relate to a 07/17/2026 vesting of performance share unit awards granted as part of issuer equity compensation. Over the prior three months, Umberger sold 5,887 shares for $133,892.22 on 07/30/2026 and 8,752 shares for $197,837.19 on 07/31/2026.
Kestra Medical Technologies reports that an affiliate plans to sell 2,380 shares of common stock through Merrill Lynch on August 3, 2026 on NASDAQ, with an indicated aggregate market value of $56,551.44. These shares relate to performance share unit awards that vested on July 17, 2026 and were granted under the issuer’s equity compensation plan. The notice also lists prior sales by Timothy Moran of 4,117 shares for $93,758.64 on July 30, 2026 and 8,759 shares for $198,000.29 on July 31, 2026.